Immortal time bias in observational studies

16 February 2021 - Observational studies are commonly used to evaluate the association between a risk factor or “exposure” and the ...

Read more →

From publication bias to lost in information

11 December 2020 - In BMJ Evidence-Based Medicine, IQWiG researchers call for a central, public and worldwide portal for clinical ...

Read more →

Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov

27 July 2020 - The coronavirus disease 2019 (COVID-19) pandemic has led to a massive activation of clinical research.  ...

Read more →

Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomised harmony

31 July 2020 - Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, substantial effort is being directed toward ...

Read more →

Regression discontinuity design

2 July 2020 - The method is used to study the outcomes related to an abrupt change when it is not ...

Read more →

The pandemic claims new victims: prestigious medical journals

14 June 2020 - Two major study retractions in one month have left researchers wondering if the peer review process is ...

Read more →

Overlap weighting: a propensity score method that mimics attributes of a randomised clinical trial

5 May 2020 - Evidence obtained from clinical practice settings that compares alternative treatments is an important source of information about ...

Read more →

Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis

16 April 2020 - Everyone wants new treatments and vaccines to address the devastation of coronavirus disease 2019 (COVID-19). ...

Read more →

Why test for proportional hazards?

13 March 2020 - The Cox proportional hazards model, introduced in 1972, has become the default approach for survival analysis in ...

Read more →

EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals

26 November 2019 - Seeking to end another flap about transparency, the European Medicines Agency has agreed to recommendations made ...

Read more →

Placebos and blinding in randomised controlled cancer clinical trials for drug and biological products: guidance for industry

28 August 2019 - This guidance provides recommendations to industry about the use of placebos and blinding in randomised controlled clinical ...

Read more →

Statement on data accuracy issues with recently approved gene therapy

6 August 2019 - As a public health agency, we believe that it is critical to facilitate the development of ...

Read more →

Surrogate endpoints in randomised controlled trials: a reality check

27 July 2019 - At the 24th Congress of the European Hematology Association in June, 2019, the results of the BELLINI ...

Read more →

European Medicines Agency is advised to take steps to avoid bias concerns over approvals

22 July 2019 - Following a two-year inquiry, the European Ombudsman has recommended the European Medicines Agency take several steps ...

Read more →

Using instrumental variables to address bias from unobserved confounders

2 May 2019 - Randomised clinical trials are considered the most reliable source of evidence for the effects of medical interventions, ...

Read more →